Skip to Content
Merck
All Photos(1)

Documents

76884

Supelco

Anthranilamide

matrix substance for MALDI-MS, ≥99.0% (HPLC)

Synonym(s):

2-AB, 2-Aminobenzamide, Anthranilic acid amide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
2-(H2N)C6H4CONH2
CAS Number:
88-68-6
Molecular Weight:
136.15
Beilstein:
508509
EC Number:
201-851-2
MDL number:
MFCD00007981
UNSPSC Code:
12000000
PubChem Substance ID:
329767409
NACRES:
NA.21

grade

matrix substance for MALDI-MS

Quality Level

100

Assay

≥99% (NT)
≥99.0% (HPLC)

form

crystals

technique(s)

MALDI-MS: suitable

mp

111-113 °C (lit.)

cation traces

Ba: ≤5 mg/kg
Ca: ≤5 mg/kg
Cd: ≤5 mg/kg
Co: ≤5 mg/kg
Cr: ≤5 mg/kg
Cu: ≤5 mg/kg
Fe: ≤30 mg/kg
K: ≤50 mg/kg
Mg: ≤5 mg/kg
Mn: ≤5 mg/kg
Na: ≤150 mg/kg
Ni: ≤5 mg/kg
Pb: ≤5 mg/kg
Zn: ≤5 mg/kg

SMILES string

NC(=O)c1ccccc1N

InChI

1S/C7H8N2O/c8-6-4-2-1-3-5(6)7(9)10/h1-4H,8H2,(H2,9,10)

InChI key

PXBFMLJZNCDSMP-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Used for non-selective, efficient fluorescent labeling of glycans. Slightly less sensitive than anthranilic acid (2-AA) for glycan labeling.

Analysis Note

metal trace analysis (ICP) corresponds to requirements

related product

Product No.
Description
Pricing

P2613

ProteoMass™ P14R MALDI-MS Standard, vial of 10 nmol

C8857

ProteoMass™ Cytochrome c MALDI-MS Standard, vial of 10 nmol, (M+H+) 12,361.96 Da by calculation

C8982

α-Cyano-4-hydroxycinnamic acid, suitable for MALDI-TOF MS

A8346

ProteoMass™ ACTH Fragment 18-39 MALDI-MS Standard, vial of 10 nmol, monoisotopic mol wt 2,464.1989 Da

I6154

ProteoMass™ Insulin chain B oxidized MALDI-MS Standard, vial of 10 nmol

I6279

ProteoMass™ Insulin MALDI-MS Standard, vial of 10 nmol, monoisotopic mol wt 5,729.6087 Da

A8471

ProteoMass™ Albumin MALDI-MS Standard, vial of 10 nmol, average mol wt 66,429.09 Da by calculation

A9096

ProteoMass™ Aldolase MALDI-MS Standard, vial of 10 nmol, average mol wt 39,211.28 Da by calculation

A8846

ProteoMass™ Angiotensin II MALDI-MS Standard, vial of 10 nmol

A8971

ProteoMass™ Apomyoglobin MALDI-MS Standard, vial of 10 nmol, (M+H+) 16,952.27 Da by calculation

B4181

ProteoMass™ Bradykinin Fragment 1-7 MALDI-MS Standard, vial of 10 nmol, monoisotopic mol wt 756.3997 Da

MSCAL1

ProteoMass™ Peptide and Protein MALDI-MS Calibration Kit, Peptide and Protein MALDI MS Calibration Standard

MSCAL2

ProteoMass™ Peptide MALDI-MS Calibration Kit, Peptide MALDI MS Calibration Standard

MSCAL3

ProteoMass™ Protein MALDI-MS Calibration Kit, Protein MALDI MS Calibration Standard

56197

3-Hydroxypicolinic acid, matrix substance for MALDI-MS, ≥99.0% (HPLC)

54793

2-(4-Hydroxyphenylazo)benzoic acid, matrix substance for MALDI-MS, ≥99.5%

85429

Sinapic acid, matrix substance for MALDI-MS, ≥99.0% (T)

03565

MALDI validation set polystyrene Mp ~700 - 70 000, certified reference material

37468

2′,6′-Dihydroxyacetophenone, matrix substance for MALDI-MS, ≥99.5%

91928

2′,4′,6′-Trihydroxyacetophenone monohydrate, matrix substance for MALDI-MS, ≥99.5%

03597

MALDI validation set PS, PMMA, PDMS, PEG and PSS Mp ~4′300 - 6′500

87884

trans-2-[3-(4-tert-Butylphenyl)-2-methyl-2-propenylidene]malononitrile, matrix substance for MALDI-MS, ≥99.0% (HPLC)

60018

Caffeic acid, matrix substance for MALDI-MS, ≥99.0% (HPLC)

29208

(N-Succinimidyloxycarbonylmethyl)tris(2,4,6-trimethoxyphenyl)phosphonium bromide, for protein sequence analysis (by MALDI-MS), ≥98.5%

46278

trans-Ferulic acid, matrix substance for MALDI-MS, ≥99.0% (HPLC)

85707

2,5-Dihydroxybenzoic acid, matrix substance for MALDI-MS, >99.0% (HPLC)

70990

α-Cyano-4-hydroxycinnamic acid, matrix substance for MALDI-MS, ≥99.0% (HPLC)

N3786

α(2→3,6,8,9) Neuraminidase from Arthrobacter ureafaciens, Proteomics Grade, suitable for MALDI-TOF MS

39468

α-Cyano-4-hydroxycinnamic acid, matrix substance for MALDI-MS, Ultra pure

39319

2,5-Dihydroxybenzoic acid, matrix substance for MALDI-MS, ≥99.5% (HPLC), Ultra pure

49508

Sinapic acid, matrix substance for MALDI-MS, ≥99.5%, Ultra pure

50862

Super-DHB, suitable for matrix substance for MALDI-MS, ≥99.0%

02241

2′,3′-Dideoxycytidine 5′-triphosphate sodium salt solution, suitable for MALDI-MS, ≥98.0% (HPLC)

42597

3′-Deoxythymidine 5′-triphosphate sodium salt solution, BioChemika, puriss. p.a., suitable for MALDI-MS, ≥98.0% (HPLC)

MS0100

ProteoMass™ Guanidination Kit, For improving MALDI-MS sensitivity and peptide sequence coverage

MSCAL4

ProteoMass™ MALDI Calibration Kit for Exactive Series MS, LTQ XL and LTQ Hybrids, MALDI MS Calibration Standard

92817

9-Aminoacridine, matrix substance for MALDI-MS, ≥99.5% (HPLC)

56451

1,5-Diaminonaphthalene, matrix substance for MALDI-MS, ≥99.0% (HPLC)

50757

Micro-Array for Mass Spectrometry (MAMS), for single cell analysis

94141

4-Chloro-α-cyanocinnamic acid, matrix substance for MALDI-MS, ≥95.0% (HPLC)

89063

4-Bromo-α-cyanocinnamic acid, matrix substance for MALDI-MS, ≥95.0% (HPLC)

77081

α-Cyano-4-fluorocinnamic acid, matrix substance for MALDI-MS, ≥95.0% (HPLC)

38419

α-Cyano-2,3,4,5,6-pentafluorocinnamic acid, matrix substance for MALDI-MS, ≥95.0% (HPLC)

39379

4-Chloro-α-cyanocinnamic acid - α-Cyano-2,4-difluorocinnamic acid mixture, matrix substance for MALDI-MS, ≥95.0% (sum of both components, HPLC)

68914

4-Bromo-α-cyanocinnamic acid - 4-Chloro-α-cyanocinnamic acid mixture, matrix substance for MALDI-MS, ≥95.0% (sum of both components, HPLC)

05851

4-Aminoquinaldine, matrix substance for MALDI-MS, ≥99.0% (HPLC)

78246

Curcumin, matrix substance for MALDI-MS, ≥99.5% (HPLC)

04973

Micro-Array for Mass Spectrometry (MAMS), for quantitative MALDI

94477

(E)-2-Cyano-3-(2-naphthyl)acrylic acid, matrix substance for MALDI-MS, ≥98.0% (HPLC)

83788

(2E)-3-(9-Anthryl)-2-cyanoacrylic acid, matrix substance for MALDI-MS, ≥97.0% (HPLC)

56229

9-Nitroanthracene, matrix substance for MALDI-MS, ≥98.5% (HPLC)

PFS11

SpheriCal™ Mix, Peptide Low, suitable for MALDI-MS

PFS31

SpheriCal™ Aqua, Peptide Medium, suitable for MALDI-MS

PFS32

SpheriCal™ Aqua, Peptide High, suitable for MALDI-MS

PFS20

SpheriCal™ Neat, Peptide Low, suitable for MALDI-MS

PFS21

SpheriCal™ Neat, Peptide Medium, suitable for MALDI-MS

PFS22

SpheriCal™ Neat, Peptide High, suitable for MALDI-MS

PFS23

SpheriCal™ Neat, Protein Low, suitable for MALDI-MS

PFS30

SpheriCal™ Aqua, Peptide Low, suitable for MALDI-MS

69028

4-Phenyl-α-cyanocinnamamide, matrix substance for MALDI-MS, ≥98.5% (HPLC)

900666

Bruker standard solvent, suitable for MALDI-MS, 50% ACN + 47.5% H2O + 2.5% TFA

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H319

Hazard Classifications

Eye Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

>365.0 °F

Flash Point(C)

> 185 °C

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCD5145
BCBW6851
BCBM7513V
BCBM7513

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yan Cai et al.
The Analyst, 138(21), 6270-6276 (2013-09-07)
Analysis of oligosaccharides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is often limited by their low ionization efficiency and inadequate fragmentation information. Derivatizations of oligosaccharides to enhance their ionization in MS are widely used, but most of these
Nicholas T Ventham et al.
PloS one, 10(4), e0123028-e0123028 (2015-04-02)
Serum N-glycans have been identified as putative biomarkers for numerous diseases. The impact of different serum sample tubes and processing methods on N-glycan analysis has received relatively little attention. This study aimed to determine the effect of different sample tubes
Antonio da Silva et al.
Leukemia & lymphoma, 55(7), 1609-1617 (2013-09-13)
Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here we report the preclinical development of the proposed biosimilar rituximab (GP2013). Post-translational modifications and bioactivities of GP2013 versus originator rituximab were engineered and monitored
Meritxell Balmaña et al.
Clinica chimica acta; international journal of clinical chemistry, 442, 56-62 (2015-01-18)
Pancreatic adenocarcinoma (PDAC) usually shows an enhanced expression of sialyl-Lewis X (sLe(x)) and related epitopes. PDAC may secrete some of the proteins carrying such increased sLe(x) determinant into serum, so they could be used as PDAC markers. Previously, we identified
Dario Venetz et al.
Proceedings of the National Academy of Sciences of the United States of America, 112(7), 2000-2005 (2015-02-04)
The ability of antibodies to extravasate out of blood vessels is critical for therapeutic activity, because molecular targets for most diseases are located outside of the endothelial lining. By performing detailed biodistribution studies with a novel IL9-armed cancer-specific antibody, we
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service